Dynavax Technologies Corporation (0IDA.L) LSE

15.49

-0.005(-0.03%)

Updated at February 09 05:37PM

Currency In USD

Dynavax Technologies Corporation

Address

2100 Powell Street

EmeryVille, CA 94608

United States of America (the)

Phone

510 848 5100

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

405

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Ryan SpencerChief Executive Officer & Director1.48M1979
Kelly MacDonaldSenior Vice President & Chief Financial Officer733,5011984
John SlebirSenior Vice President & General Counsel809,1291965
Robert JanssenChief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs827,7191954
David F. NovackSenior VP & COO965,3131962
Donn CasaleSenior Vice President & Chief Commercial Officer0N/A
Eric FringsVice President, Site Head & MD for Dynavax GmbH0N/A
Jeff CoonSenior Vice President & Chief Human Resources Officer01963
Joseph MetzingerVice President & Chief Accounting Officer01984
Paul CoxVice President of Investor Relations & Corporate Communications0N/A
Dong YuSenior Vice President of Research0N/A

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.